A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity. 2016

Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

A novel HIV-1 inhibitor, 6-(tert-butyl)-4-phenyl-4-(trifluoromethyl)-1H,3H-1,3,5-triazin-2-one (compound 1), was identified from a compound library screened for the ability to inhibit HIV-1 replication. EC50 values of compound 1 were found to range from 107.9 to 145.4 nm against primary HIV-1 clinical isolates. In in vitro assays, HIV-1 reverse transcriptase (RT) activity was inhibited by compound 1 with an EC50 of 4.3 μm. An assay for resistance to compound 1 selected a variant of HIV-1 with a RT mutation (RTL100I ); this frequently identified mutation confers mild resistance to non-nucleoside RT inhibitors (NNRTIs). A recombinant HIV-1 bearing RTL100I exhibited a 41-fold greater resistance to compound 1 than the wild-type virus. Compound 1 was also effective against HIV-1 with RTK103N , one of the major mutations that confers substantial resistance to NNRTIs. Computer-assisted docking simulations indicated that compound 1 binds to the RT NNRTI binding pocket in a manner similar to that of efavirenz; however, the putative compound 1 binding site is located further from RTK103 than that of efavirenz. Compound 1 is a novel NNRTI with a unique drug-resistance profile.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014227 Triazines Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazine,Benzotriazines
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
June 2015, Molecules (Basel, Switzerland),
Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
May 1999, Biochemical and biophysical research communications,
Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
December 1997, Farmaco (Societa chimica italiana : 1989),
Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
December 1990, Science (New York, N.Y.),
Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
March 1992, Biochemical pharmacology,
Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
January 1995, Virology,
Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
January 2002, Planta medica,
Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
March 2014, Chinese journal of natural medicines,
Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
January 2011, Antiviral therapy,
Emiko Urano, and Kosuke Miyauchi, and Yoko Kojima, and Makiko Hamatake, and Sherimay D Ablan, and Satoshi Fudo, and Eric O Freed, and Tyuji Hoshino, and Jun Komano
August 1993, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!